Evidence map›Paper›PMID 33392433›Full record

ReviewAging medicine (Milton (N.S.W))2020

Clinical perspectives and concerns of metformin as an anti-aging drug.

Chuyao Wang, Bangwei Chen, Qian Feng, Chao Nie, Tao Li

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Aging medicine (Milton (N.S.W)), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Vascular Aging: Assessment and Intervention.Clinical interventions in aging · 2023
    Review
  10. Review
  11. We are all aging, and here's why.Aging medicine (Milton (N.S.W)) · 2022
    Review
  12. Review
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chuyao WangBGI-Shenzhen Beishan Industrial Zone Shenzhen China.ORCID https://orcid.org/0000-0002-4704-1331
Bangwei ChenBGI-Shenzhen Beishan Industrial Zone Shenzhen China.
Qian FengBGI-Shenzhen Beishan Industrial Zone Shenzhen China.
Chao NieBGI-Shenzhen Beishan Industrial Zone Shenzhen China.
Tao LiBGI-Shenzhen Beishan Industrial Zone Shenzhen China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As percentages of elderly people rise in many societies, age-related diseases have become more prevalent than ever. Research interests have been shifting to delaying age-related diseases by delaying or reversing aging itself. We use metformin as an entry point to talk about the important molecular and genetic longevity-regulating mechanisms that have been extensively studied with it. Then we review a number of observational studies, animal studies, and clinical trials to reflect the clinical potentials of the mechanisms in lifespan extension, cardiovascular diseases, tumors, and neurodegeneration. Finally, we highlight remaining concerns that are related to metformin and future anti-aging research.

Indexed as

agingclinical pharmacologylongevitymetformin

Identifiers

PMID33392433
PMCPMC7771567

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.